The relationship between LTC4S, ALOX5 genetic polymorphism and clinical efficacy of leukotriene receptor modula-tors in children with asthma
10.3969/j.issn.1000-3606.2014.12.007
- VernacularTitle:哮喘儿童白三烯受体调节剂临床疗效与白三烯C4合成酶及5-脂氧化酶基因的相关性
- Author:
Shuhua YUAN
;
Yong YIN
;
Wenfang DONG
;
Hao ZHANG
;
Wei WANG
;
Lei ZHANG
;
Jing ZHANG
- Publication Type:Journal Article
- Keywords:
asthma;
leukotriene C4 synthase;
5-lipoxygenase;
polymorphism;
leukotriene receptor antagonist
- From:
Journal of Clinical Pediatrics
2014;(12):1126-1131
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effect of genetic polymorphism of leukotriene C4 synthase (LTC4S) and 5-lipoxy-genase (ALOX5) on efifcacy of leukotriene receptor antagonist (LTRA) in children with moderate persistent asthma. Methods Seventy-two children with moderate persistent asthma who visited the out-patient clinic of Shanghai Children’s Medical. Center from June 2011 to June 2013 were divided into two groups, each of which ifrst had ICS or LTRA+ICS for twelve weeks and then had the other for another twelve weeks. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to assess the genetic polymorphism of LTC4S RS730012 and ALOX5 RS2115819. Pulmonary function, clinical symptoms and C-ACT score were evaluated before and after treatment. Results After the treatment with LTRA, 75%forced expiratory lfow (FEF75) was improved more signiifcantly in patients with A/C or C/C genotype at LTC4S (RS730012) locus than in patients with A/A genotype. After the treatment with LTRA+ICS, there was no difference of pulmonary function among patients with different genotypes at ALOX5 (RS2115819). Conclusions The SNP of LTC4S (RS730012) is associated with the efifcacy of montelukast in asthmatic patients because of the improvement of small airway function.
